Latest news with #TevaPharmaceutical
Yahoo
4 days ago
- Health
- Yahoo
Teva 2024 Healthy Future Report: Health System Strengthening and Capacity Building
NORTHAMPTON, MA / / June 6, 2025 / Teva Pharmaceutical: At Teva, we are all in for better health. Increasing access to quality medicines is fundamental to improving the health of patients and the success of our business. In order to achieve lasting impact, we have expanded a number of our access programs to go beyond the product by incorporating Health System Strengthening and Capacity Building efforts. Capacity building is critical for ensuring sustainable and resilient healthcare systems, directly contributing to our mission of expanding access to care. To increase our positive impact beyond medicines, our health system strengthening and capacity-building initiatives expand healthcare professionals' skill sets, increase treatment accessibility such as diagnosis and screening, improve community members' health literacy and awareness and overall enhance local capacity to support the health needs of underserved populations. We take a holistic approach to health equity to address other social determinants of health, including financial, geographic, socioeconomic and cultural factors. We aim to increase the cumulative number of beneficiaries of our initiatives by 200% by 2026 (vs. cumulative 2022-2023 baseline). Many of our initiatives complement our Access to Medicines programs (see page 19 in the Healthy Future Report). Our main initiatives in 2024 to promote health system strengthening and capacity-building were: Malawi, Uganda, Botswana, Tanzania and Rwanda - Pediatric oncology specialists are few and far between in Sub-Saharan Africa. We expanded our support for Global HOPE in 2024 through efforts specifically focused on strengthening local capacity, including training for nurses and medical officers, as well as nurse training scholarships. Beneficiaries in 2024 numbered 1,965 - including HCPs trained and resulting patients diagnosed. We are building sustainable healthcare capacity, ensuring that children receive timely and effective treatment. Ghana - A lack of breast care centers and trained healthcare practitioners, along with low awareness and high stigma, contribute to high breast cancer mortality rates in Ghana. Through our partnership with Breast Care International, we are addressing healthcare challenges that hinder early diagnosis and treatment, ensuring that patients receive the care they need. We are raising awareness on breast cancer and the importance of early diagnosis, increasing local capacity to increase breast cancer screening for women aged 18-60, and improving referral pathways. Beneficiaries in 2024 totaled 10,752, including patients and HCPs in rural Ghana. Chile - We organized an educational event focusing on mental health, the risks of self-medication and the importance of adhering to prescribed therapies, attracting 100 participants including healthcare professionals and community members. We conducted community training sessions in Cochamó and Río Puelo, collectively impacting around 5,100 residents. USA - From November 2023 to October 2024, our grant funding helped 34,916 beneficiaries (14,480 directly and 20,436 indirectly) in clinics supported by our Community Routes program. Over two years of funding, we have trained 2,800 community members, held 131 community events, expanded access to mental health services for 63,659 beneficiaries and conducted 24,617 patient screenings. Together with our partners Direct Relief and NAFC, in 2024 we published a report in collaboration with the grantees of our behavioral health program in local USA clinics and communities. Lessons Learned from Community Routes: Access to Mental Health Care highlights experiences and understandings relevant for broader underserved, bi-lingual/bi-cultural populations and patients with low health literacy. The report is a useful resource for social impact program policymakers, funders and safety-net providers. Support the Soul in IsraelFollowing the brutal attacks of October 7, 2023 trauma took hold of the lives of Israelis, affecting citizens with post-traumatic stress disorder and related issues such as depression, anxiety, sleep disorders and addictions. Israel needs more professional trauma therapists as the shortage hampers mental health support and recovery. Therapists are also experiencing burnout, as well as dealing with intense personal challenges. Our Support The Soul program provides support via: training professional teams, creating safe spaces, innovative tools, and research. It is strengthening the infrastructure of resilience centers to provide safe spaces for therapy, increasing treatment facilities and making mental health services more accessible. In collaboration with the Israel Trauma Coalition, our training courses in Israel in 2024 included 32 hours of instruction for 430 practitioners that benefited over 2,580 individuals in need. Support the Soul will continue through 2025, aiming to train and supervise 750 professional therapists, support two resilience centers (benefiting 6,000 people directly), equip 2,000 first responders with resilience tools, and support 18 technology companies through a southern-based acceleration program. To learn more, read the full 2024 Healthy Future the full 2024 Healthy Future Report Disclosures. Patient who is part of the Global Hope Program in Uganda View additional multimedia and more ESG storytelling from Teva Pharmaceutical on Contact Info: Spokesperson: Teva PharmaceuticalWebsite: info@ SOURCE: Teva Pharmaceutical View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Health
- Yahoo
Asia-Pacific Transdermal Skin Patches Market Outlook 2025-2033: Trends for Pain Relief, Smoking Reduction & Cessation Aid, Overactive Bladder, Hormonal Therapy, and Other Applications
Innovations in microneedle and smart patch technologies are boosting efficacy and compliance, while government healthcare initiatives enhance access. Major players include Teva Pharmaceutical, 3M, and Johnson & Johnson. Growth is notably strong in China, India, and Japan due to demographic and health trends. Asia-Pacific Transdermal Skin Patches Market Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Transdermal Skin Patches Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to Asia-Pacific Transdermal Skin Patches Market is expected to reach US$ 3.96 billion by 2033 from US$ 2.76 billion in 2024, with a CAGR of 4.10% from 2025 to 2033. Increasing prevalence of chronic diseases, aging population, requirement for pain-free drug delivery, technological innovation, growth in healthcare infrastructure, and rising awareness of self-administered therapies that ensure convenience and improved patient compliance are the key drivers of the transdermal skin patches market in Asia-Pacific. Several significant factors are behind the consistent rise of the transdermal skin patch market in Asia-Pacific. The increasing prevalence of chronic conditions such as diabetes, hypertension, and cardiovascular disease is a key driver, since it increases the need for safe, non-invasive drug delivery systems. Increased demand for user-friendly and convenient pharmaceutical solutions is also being driven by the ageing population in the region, most notably in countries such as China and Japan. Efficiency in drug delivery and compliance among patients are being enhanced by advances in technology in the form of smart patches and microneedle technology. In addition, the application of transdermal therapies in the region is being encouraged and access enhanced by government healthcare initiatives as well as increases in healthcare infrastructure. Growth Drivers for the Asia-Pacific Transdermal Skin Patches MarketRising prevalence of respiratory disease The Asian Pacific market for transdermal skin patches is growing largely because of the rising prevalence of chronic diseases. Owing to sedentary lifestyles, environmental influences, and aging populations, chronic conditions such as diabetes, cardiovascular diseases, COPD, and cancer are on the rise. The incidence of chronic obstructive pulmonary disease (COPD) in Indian non-smokers, for instance, ranged from 1.6% to 26.6%, a meta-analysis study published in the Reviews on Environmental Health journal in November 2023 revealed. Also, India detects over 1.39 million new cancer cases every year, the Kidwai Memorial Institute of Oncology says. Long-term medication is often required for most diseases, and transdermal patches offer a steady, non-invasive, and effective route of drug delivery that enhances patient compliance. Demand for effective and convenient treatment options, like transdermal patches, is expected to grow tremendously across the region as the incidence of chronic diseases rises. Technological Advancements The Asia-Pacific market for transdermal skin patches is growing with a swift pace due to technology advancements that raise patient comfort, therapeutic efficacy, and medication administration effectiveness. Transdermally treatable disorders have widened as a result of innovations such as microneedle patches, sensor-embedded smart patches, and better adhesives. These technologies enhance patient compliance, especially among the elderly and the chronically ill, through the delivery of controlled, sustained, and painless medication. Teikoku Seiyaku Co. Ltd. and Kowa Company Ltd.'s April 2023 marketing in Japan of ALLYDONE Patches 27.5 mg and 55 mg for the treatment of dementia caused by Alzheimer's disease is a good case in point. This launch highlights how innovative patch technologies can be employed to treat neurologic diseases. These technological innovations are expected to greatly boost the adoption of transdermal patches across the Asia-Pacific market as research and development proceed. Ageing Population The aging population of the Asia-Pacific region is one of the key drivers of the market for transdermal skin patches. The demand for non-invasive, easy-to-use medicine delivery methods is increasing as the elderly population grows, especially in countries such as China and Japan. China's National Bureau of Statistics announced in January 2022 that the nation's population would be around 1.412 billion in 2021 and is likely to increase to 1.43 billion by the year 2026. Due to their ease of use, sustained drug delivery, and minor side effects, transdermal patches are a preferred option for this aging group, which is often required to take long-term medication for ongoing diseases. The demand for transdermal patches in the region is being fueled by the ability to administer medicine oneself without constant hospital visits, which fits the demands of an aging population. The demand for these advanced distribution systems is expected to evolve further as the number of elderly individuals increases. Challenges in the Asia-Pacific Transdermal Skin Patches MarketLimited Drug Permeability One major obstacle facing the Asia-Pacific transdermal skin patch business is limited medication permeability. The kinds of pharmaceuticals that can be administered via patches are limited by the ineffectiveness of certain drugs un penetrating the epidermal barrier. This restriction lessens the transdermal patches' adaptability and keeps them from being applied to a wider variety of conditions. Skin penetration technologies are being improved by researchers, but this problem will prevent the market from expanding until these developments are widely adopted. Skin Irritation and Sensitivity Significant obstacles in the Asia-Pacific transdermal skin patch industry are skin sensitivity and irritation. Patients may stop wearing the patches regularly if they experience skin problems including rashes, redness, or allergic reactions after using them for an extended period of time. This may limit the market's potential and lower patient compliance. Manufacturers are working to address this by creating hypoallergenic, skin-friendly materials and advancing patch adhesive methods to reduce irritation and improve user comfort, but these issues continue to exist. Key Attributes Report Attribute Details No. of Pages 200 Forecast Period 2024-2033 Estimated Market Value (USD) in 2024 $2.76 Billion Forecasted Market Value (USD) by 2033 $3.96 Billion Compound Annual Growth Rate 4.1% Regions Covered Asia-Pacific Key Topics Covered1. Introduction2. Research & Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Asia-Pacific Transdermal Skin Patches Market5.1 Historical Market Trends5.2 Market Forecast6. Asia-Pacific Transdermal Skin Patches Market Share Analysis6.1 By Type6.2 By Application6.3 By Distribution Channel6.4 By Countries7. Type7.1 Matrix7.2 Reservoir7.3 Drug-in-Adhesive7.4 Other Types8. Application8.1 Pain Relief8.2 Smoking Reduction and Cessation Aid8.3 Overactive Bladder8.4 Hormonal Therapy8.5 Others9. Distribution Channel9.1 Hospital Pharmacies9.2 Retail Pharmacies9.3 Online Pharmacies10. Countries10.1 China10.2 Japan10.3 India10.4 South Korea10.5 Thailand10.6 Malaysia10.7 Indonesia10.8 Australia10.9 New Zealand10.10 Rest of Asia-Pacific11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Key Players Analysis13.1 Teva Pharmaceutical Industries Ltd.13.2 3M Company13.3 Nitto Denko Corporation13.4 Johnson & Johnson13.5 Luye Pharma Group13.6 Bayer AG13.7 Novartis AG13.8 Beiersdorf AG13.9 Viatris Inc.13.10 Abbott Laboratories For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Asia-Pacific Transdermal Skin Patches Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
09-05-2025
- Business
- Yahoo
Why Teva Pharmaceutical Stock Is Soaring Today
Teva reported Q1 earnings, beating Wall Street's EPS expectations. The company raised its full-year guidance as margins expand. 10 stocks we like better than Teva Pharmaceutical Industries › Shares of Teva Pharmaceutical (NYSE: TEVA) are surging on Wednesday. The company's stock is up 9.2% as of 1:15 p.m. ET and was up as much as 9.5% earlier in the day. The leg up comes as the S&P 500 is up 0.4% and the Nasdaq Composite is losing 0.1% on the day so far. The Israel-based pharmaceutical company reported strong Q1 earnings today and raised its full-year profit guidance. Teva reported Q1 adjusted earnings per share (EPS) of $0.52, solidly beating Wall Street's target of $0.48. The company missed on sales, however, reporting $3.89 billion for the quarter when $4 billion was expected. Still, the company's margins are expanding, reaching 48.2% in the quarter, compared to 46.4% a year ago. The company pointed to higher-margin specialty drugs representing a larger portion of overall sales this quarter. One of these drugs, Austedo, which is used to treat movement disorders, continued its strong performance with worldwide revenue of $411 for the quarter, up 39%, compared to the same period last year. Teva raised its fiscal 2025 adjusted EPS guidance from a range of $2.35 to $2.65 to a new range of $2.45 to $2.65. The new midpoint exceeds the consensus estimate of $2.55. CEO Richard Francis emphasized that Teva is now entering the "Acceleration Phase" of its "Pivot to Growth Strategy." "We're accelerating innovative growth and strengthening our generics business, while streamlining our operations, sharpening our business, and optimizing processes," Francis stated. These efficiency measures, combined with the company's product growth, appear to be resonating with investors. The company appears to be delivering on its growth plan. Considering its reasonable valuation, I think the stock is a good pick. Before you buy stock in Teva Pharmaceutical Industries, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Teva Pharmaceutical Industries wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $613,546!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $695,897!* Now, it's worth noting Stock Advisor's total average return is 893% — a market-crushing outperformance compared to 162% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 5, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Teva Pharmaceutical Stock Is Soaring Today was originally published by The Motley Fool
Yahoo
08-05-2025
- Business
- Yahoo
Why Teva Pharmaceutical Industries Limited (TEVA) Skyrocketed On Wednesday
We recently published a list of . In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands against other Wednesday's best-performing stocks. The stock market rebounded on Wednesday, with all major indices ending in the green as investors cheered the Federal Reserve's decision to keep interest rates unchanged. On Wednesday afternoon, the Fed kept rates steady at a range of 4.25 percent to 4.5 percent, saying that it was not in a hurry to cut rates and could still 'wait and see' the impact of President Donald Trump's tariff policies. The Dow Jones rallied by 0.70 percent, the S&P 500 increased by 0.43 percent, and the Nasdaq grew by 0.27 percent. Beyond the major indices, 10 firms stood out with strong gains, thanks to a flurry of fresh developments, including new partnerships, optimistic outlooks, and impressive earnings performance. In this article, we name Wednesday's 10 best-performing stocks and detail the reasons behind their gains. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company. Teva Pharmaceutical grew its share prices by 9.18 percent on Wednesday to end at $17.60 apiece as investors cheered the company's 9th consecutive quarter of impressive revenue performance. In its earnings release, Teva Pharmaceutical Industries Limited (NYSE:TEVA) said it achieved a 2-percent increase in revenues in the first three months of the year at $3.89 billion from the $3.82 billion registered in the same period last year, thanks to the higher contribution from Austedo and Uzedy's US operations, coupled with sales from its generic products across all other segments. The strong figures pushed the company to profitability during the quarter, having swung to an attributable net income of $214 million versus a $139 million net loss year-on-year. Looking ahead, Teva Pharmaceutical Industries Limited (NYSE:TEVA) posted a generally optimistic outlook for its business, saying that US tariffs are expected to have an immaterial impact. For the full year 2025, the company expects revenues to settle anywhere between $16.8 billion and $17.2 billion. Overall, TEVA ranks 9th on our list of Wednesday's best-performing stocks. While we acknowledge the potential of TEVA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than TEVA but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
